BALA CYNWYD, PA — Larimar Therapeutics, Inc. (Nasdaq: LRMR) is set to present pivotal data from its nomlabofusp Phase 1 and ...

Larimar Therapeutics Inc (LRMR) stock saw a modest uptick, ending the day at $7.14 which represents a slight increase of $0.29 or 4.23% from the prior close of $6.85. The stock opened at $7.08 and ...

Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare ...

Fintel reports that on September 12, 2024, Jones Trading initiated coverage of Larimar Therapeutics (NasdaqGM:LRMR) with a ...

Ataxia Market Set To Witness Significant Growth By 2024-2031: Pfizer, Inc., CRISPR Therapeutics, Sanofi, Bio-Techne Ataxia market is estimated to be valued at US$ 30,880.5 million in 2024 and is ...

Larimar Therapeutics Inc (LRMR) stock saw a decline, ending the day at $8.05 which represents a decrease of $-0.85 or -9.55% from the prior close of $8.9. The stock opened at $8.92 and touched a low ...

Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR) today announced that the United States Food and Drug Administration (FDA) has selected nomlabofusp to participate in the Support ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Baird has initiated coverage on Larimar Therapeutics (NASDAQ: LRMR) with an Outperform rating and set a price target of $16.00. The firm's optimism is anchored in the potential U.S. approval of ...